拜耳(ADR)股票討論區

CEO Anderson faces pressure to improve Bayer's financial health after deciding not to sell its consumer-health business. The effectiveness of cost-cutting plans and cash conversion efficiency remain uncertain. The ongoing Roundup litigation continues to loom over the company's future.

Claimant's attorneys believe the jury's punitive damages award sends a clear message for top-to-bottom change in this multi-national corporation. Bayer, however, remains confident in its strong arguments on appeal to overturn this verdict or at least reduce the unconstitutionally excessive damages.

Altman joins Microsoft
Sam Altman, who was ousted as CEO of OpenAI on Friday, is joining Microsoft to lead a new artificial intelligence team. Greg Brockman, former OpenAI president and board chair — and potentially many OpenAI employees — will join Microsoft alongside Altman. One researcher said the move's a case of "damage control." But investors begged to differ, pushing Microsoft shares to a record high.
Tech excitement
U.S. markets traded higher Monday, led by e...

Analysts see Bayer's trial failures as a major setback, hinting at challenges for its Pharma business. Ashtead's slight profit downgrade reflects investors' harsh reactions to less optimistic trade outlooks.

Court ruling contradicts Bayer's safety claims for glyphosate, Roundup's ingredient, causing confusion. However, Bayer remains confident in glyphosate's safety and agricultural importance, in spite of court setbacks.

Deutsche Bank analysts led by Falko Friedrichs consider the new CEO's seriousness about the company's structural options as a potentially positive development, which might result in actions taken sooner than later.

Bayer suggests the direct-seeded rice cultivation method may transform agriculture through environmental benefits and alignment with regenerative agriculture. It predicts positive impacts on water, labor, and emissions.